Loading stock data…
RGEN
$117.20-1.11 (-0.94%)
Market ClosedLast close May 1
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Repligen Corporation in the Healthcare sector is trading at $117.20. The stock is currently near its 52-week low of $109.50, remaining 15.1% below its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why RGEN maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$117.20
Potential Downside
86.5%
Whystock Fair Value$15.80
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus18 analysts
Buy
Mean target$179.78+53.4%
Range$140.00 – $220.00
Fundamentals
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatogr...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.43B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
132.58
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-0.66%
Volume
Today's trading volume
751,851
Recent News
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Repligen (RGEN) Starting To Look Attractive After Its Sharp Share Price Pullback
Wondering if Repligen at around US$113 is starting to look interesting on price, or if the recent weakness is telling you to be cautious about its value? The stock closed at US$113.11, with returns of a 0.8% decline over 7 days, 4.0% decline over 30 days, 31.2% decline year to date, and 17.6% decline over the past year. These moves may have shifted how investors think about its growth potential and risk profile. Over the past few months, attention has focused on Repligen in the context of...
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tempered Forward Expectations Hurt Repligen Corp. (RGEN) in Q1
Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The first quarter of 2026 began with optimism about the domestic economy and attractive Small Cap valuations, but was impacted by volatility from Middle East geopolitical unrest and changing interest rate expectations. This unrest drove […]
Why Repligen (RGEN) Shares Are Plunging Today
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 5.3% in the afternoon session after an SEC filing revealed that the company's Chief Executive Officer, Olivier Loeillot, sold company stock.